Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Information
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Communications
Publications
Investor Presentations
In the News
Posters
Publications
Contact Us
Contact Us
Email Alerts
Investor Information
Investor Information
>
ASX Announcements
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
10 Apr 2024
AACR Conference Presentation
27 Mar 2024
Update on ACCENT Trial in Pancreatic Cancer
30 Jan 2024
Quarterly Activities/Appendix 4C Cash Flow Report
18 Jan 2024
FDA Clearance Amplia's IND for Pancreatic Cancer Trial in US
17 Jan 2024
Amplia Reports First Patient Dosing In Phase 2a Accent Trial
02 Jan 2024
Change of Director's Interest Notice - Dr Warwick Tong
02 Jan 2024
Change of Director's Interest Notice - Dr Chris Burns
02 Jan 2024
Change of Director's Interest Notice - Dr Robert Peach
02 Jan 2024
Change of Director's Interest Notice - Jane Bell
02 Jan 2024
Notification of cessation of securities - ATX
Previous
1
2
3
Next